Author: Ravi Shankar

WEKA’s AI data storage and memory capabilities will support Smartbird’s dedicated AI clusters as part of a broader strategy to build a network of leading technology partners

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Smartbird, Inc. (NASDAQ: BIRD), the enterprise AI infrastructure company, and WEKA, the AI data and memory infrastructure company, today announced a partnership to deliver managed AI infrastructure services for enterprise AI workloads. By combining WEKA NeuralMesh software with Smartbird’s dedicated AI clusters, the offering gives enterprises a fully managed AI infrastructure foundation that is sovereign by design and ready for production workloads from day one.

The agreement marks the first in a broader network of infrastructure ecosystem partnerships that will support Smartbird’s strategy to deliver a proven stack of best-of-breed technologies as a fully-managed, enterprise-grade AI infrastructure service.

Why It Matters Now: Production AI Demands Infrastructure Enterprises Can Control

As AI moves to production scale and adopts agentic AI applications that operate continuously, infrastructure economics become increasingly important: GPU utilization, power consumption, and cost per token can determine whether AI initiatives scale or stall.

At the same time, many organizations, particularly in highly regulated industries such as government, healthcare, and financial services, cannot move sensitive data into shared public cloud environments. Some also lack in-house teams with the specialized expertise to build and operate advanced AI infrastructure. Smartbird is focused on serving these organizations, offering dedicated, sovereign, private AI infrastructure delivered and operated as a managed service.

“Enterprises don’t want to assemble AI infrastructure from individual parts. They want a complete solution that works, operated by people who have done this before,” said Dr. Nadia Carlsten, president and CEO of Smartbird. “Every Smartbird AI cluster is designed around the customer’s specific requirements, whether they’re a bank, a hospital, a manufacturer, or a government agency. By incorporating WEKA NeuralMesh, Smartbird gives customers a data and memory layer proven to perform at scale. This partnership reflects our approach to building infrastructure: experienced partners, trusted technologies, and disciplined execution.”

Workload-First, Customer-First: Dedicated AI Infrastructure

Launched in June 2026, Smartbird designs, builds, and operates dedicated AI clusters for enterprises. Each cluster is delivered as a managed service, designed for the customer’s specific workloads and deployed either on-premises or in a dedicated colocation environment.

A Proven Technology Stack

Smartbird clusters incorporating WEKA NeuralMesh software deliver:

• High-performance data and memory infrastructure. Customers can deploy rapidly and ensure GPUs are continuously supplied with data, with throughput reaching hundreds of gigabytes per second.
• Fully managed, end-to-end. Smartbird delivers and operates the complete infrastructure stack: facilities, compute, networking, data infrastructure, and data orchestration. Customers get one accountable partner without having to integrate multiple vendors or manage multiple hardware release cycles.
• Sovereign by design. Customer data stays within a customer-controlled environment and runs on fully dedicated infrastructure, providing the isolation, encryption, and auditability that regulated industries require.
• A fast, efficient foundation for inference and agentic AI. As enterprise AI shifts from periodic training to persistent inference and agentic applications, the Smartbird-WEKA solution expands GPU memory capacity, shortens time to first token, and reduces recomputation, thereby lowering token costs.

“Agentic AI is unforgiving: idle GPUs and stalled pipelines land straight on the P&L statement. Enterprises have been told the fix is a tradeoff, performance or sovereignty, but that was always a failure of infrastructure, not a law of physics,” said Liran Zvibel, co-founder and CEO at WEKA. “WEKA NeuralMesh ends the tradeoff. Smartbird delivers it as dedicated clusters customers don’t have to build or operate. Together, we’re giving regulated industries production AI that runs at full speed, on infrastructure only they touch, with more output per GPU, per watt and per dollar.”

Enterprises interested in building with Smartbird can visit www.smartbird.ai. To learn more about WEKA’s AI data storage and memory solutions, visit www.weka.io/product/neuralmesh/.

About Smartbird
Smartbird, Inc. (NASDAQ: BIRD) designs, builds, and operates dedicated AI infrastructure for enterprises. Delivered as a managed service, Smartbird provides the performance, control, and security of dedicated infrastructure without requiring customers to shoulder the capital investment and operational complexity of running it themselves. Each Smartbird cluster is mapped 1:1 to its customer and deployed on-premises or in a dedicated colocation environment, with data center sites under development in the U.S. and Europe. Smartbird is headquartered in Palo Alto. Learn more at smartbird.ai.

About WEKA
WEKA is the AI data and memory infrastructure company transforming the economics of agentic AI. The WEKA® NeuralMesh™ platform unifies high-performance data storage with extended GPU memory, giving enterprises, AI cloud providers, and AI builders a single foundation for training, inference, and agentic workloads. With Augmented Memory Grid, NeuralMesh extends GPU memory capacity by 1000x, accelerates time to first token by up to 20x, and delivers 10x more concurrent users from the same GPU footprint, proven in production benchmarks. Trusted by 30% of the Fortune 50, WEKA enables organizations to scale AI faster, optimize GPU utilization, and reduce the cost of every token served. Learn more at www.weka.io or connect with us on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Smartbird’s strategy, anticipated partnerships, expected data center availability and cluster deployments, capital resources and market opportunity. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risks described in Smartbird’s filings with the U.S. Securities and Exchange Commission. Smartbird undertakes no obligation to update these forward-looking statements except as
required by law.

Media & IR Contacts

For Smartbird
Smartbird Investor Relations: ir@smartbird.ai
Smartbird Media Relations: press@smartbird.ai

For WEKA
WEKA Communications: pr@weka.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e2e0b632-0bff-4250-b6c0-2adbd47926cc

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to provide an update on its ongoing diamond drilling program at the D Zone silver-lead-zinc target, located within its flagship Magno Project in northwestern British Columbia.

Highlights

• Four of five completed drill holes intersected semi-massive to massive sulphide mineralization at Middle D.
• GOH26-10 and GOH26-13 intersected approximately 10.75 metres and 13 metres, respectively, of cumulative sulphide mineralization across separate intervals.
• GOH26-10 encountered multiple mineralized horizons containing visible galena and sphalerite, together with arsenopyrite-rich sulphides and garnet-bearing skarn, highlighting the polymetallic character of the target.
• Preliminary portable XRF screening of selected drill-core locations in GOH26-10 returned individual spot readings of up to 411,000 ppm zinc (41.1% Zn), 38,500 ppm lead (3.85% Pb) and 17,600 ppm tin (1.76% Sn), with laboratory assays pending.*

*Portable XRF readings are preliminary, non-representative spot measurements and should not be interpreted as laboratory assays or indicative of interval grades.

GoldHaven has completed five diamond drill holes from two drill pads approximately 75 metres (m) apart within the Middle D area of the historically named D Zone, with four of the five completed holes intersecting semi-massive to massive sulphide mineralization within a geophysical anomaly identified in an airborne survey conducted by the Company in early 2026.

The Company is currently advancing drill hole GOH26-14 as it continues to evaluate the distribution and geometry of mineralization within the target area.

D Zone Drilling Results

The current drilling campaign is focused on evaluating the Middle D portion of the D Zone, an area of historically documented silver-lead-zinc mineralization within the Magno Project.

Rob Birmingham, President and CEO of GoldHaven, commented:

“We are encouraged by the results at D Zone, with four of our first five drill holes intersecting significant intervals of semi-massive to massive sulphide mineralization. The identification of multiple mineralized horizons, including visible lead-zinc sulphides and indications of tin-bearing skarn, is particularly interesting.

“These early results are helping us build a better understanding of the system and guide our next exploration targets. With drilling continuing and assays pending, we look forward to evaluating the potential of D Zone alongside our ongoing tungsten exploration at Kuhn.”

Table 1: D Zone Drilling Summary

DRILL HOLE ID	SULPHIDE MINERALIZATION INTERVAL APPROXIMATE LENGTH (m)	DEPTH (m)
GOH26-09	not-encountered	not applicable
GOH26-10	10.75 m	58.8-62.15 m; 91.9-98.0 m; 134.2-135.5 m
GOH26-11	0.1 m	62 m
GOH26-12	1.0 m	68-69 m
GOH26-13	13.0 m	13-17 m; 20-29 m
GOH26-14	in progress	–

Reported intervals represent visual geological observations along drill core and are not necessarily true widths. Assay results are pending. The presence of sulphides does not necessarily indicate economically significant grades of silver, lead, zinc or other metals.

Figure 1: Middle D Zone 2026 drill locations and sulphide intersections. Intervals represent downhole lengths, not true widths. Assays pending.

Detailed Geological Observations – GOH26-10

GOH26-10 intersected four distinct mineralized zones between approximately 58.8 and 138.1 metres downhole, including 10.75 metres of cumulative semi-massive to massive sulphide mineralization and an additional 0.7 metres of mineralized skarn across separate intervals.

The upper zone (58.8–62.15 m) contains visible galena and sphalerite associated with pyrite and pyrrhotite. Deeper intervals (91.9–98.0 m and 134.2–135.5 m) contain predominantly pyrite, pyrrhotite and arsenopyrite, with locally observed sphalerite, reported cassiterite and hematite alteration. A fourth interval (137.4–138.1 m) comprises garnet-bearing, hematite-altered skarn.

These contrasting mineral assemblages may reflect different mineralization conditions within the D Zone system and will help guide ongoing geological interpretation and exploration targeting.

Figure 2: Drill core from GOH26-13 showing visually prominent metallic sulphide mineralization within the Middle D Zone at GoldHaven’s Magno Project.

Figure 3: Drill core from GOH26-10 showing sulphide mineralization within the upper polymetallic replacement-style zone, where geological logging identified galena and sphalerite associated with pyrite and pyrrhotite.

Preliminary Portable XRF Observations

Portable X-ray fluorescence (pXRF) screening of selected drill core using a SciAps X-505 handheld analyzer returned individual spot readings of up to 411,000 ppm zinc (41.1% Zn) at 134.6 metres, 280,500 ppm zinc (28.05% Zn) and 38,500 ppm lead (3.85% Pb) at 61 metres, and 17,600 ppm tin (1.76% Sn) at 93.6 metres in GOH26-10.

These preliminary measurements were obtained from select locations on heterogeneous mineralized core for geological screening purposes. They are subject to analytical limitations, including potential matrix effects, and are not laboratory assays or representative of grades across the reported drill intervals. Laboratory assays are pending and may differ materially from the pXRF readings.

The SciAps X-505 handheld pXRF analyzer is calibrated before each use using the manufacturer-provided calibration plate. Geochemical reference standards used in the drill program’s QA/QC procedures are also analyzed regularly with the pXRF to monitor instrument performance.

Historical Mineralization and Exploration Potential

The D Zone has been the subject of historical exploration, including drilling that reportedly intersected significant silver-lead-zinc mineralization.

Historical results include a reported interval of 7.6 metres grading 240 g/t silver, 4.73% lead and 4.74% zinc, providing context for the mineralization historically encountered in the broader D Zone area.

Historical results are from 1982 exploration drilling and have not been independently verified by the Company. They are provided for historical context and are not necessarily indicative of current drilling results.

GoldHaven’s 2025 surface exploration program also identified high-grade polymetallic mineralization across portions of the Magno Project.

The Company is investigating whether the sulphide mineralization encountered in the current drilling is associated with the historically documented mineralized system and how the mineralized intervals relate to one another. The Middle D area is located in a geophysical anomaly identified in the airborne survey conducted in early 2026.

Historical drill results and surface samples are not necessarily representative of grades or widths in the current drill holes.

Next Steps

GoldHaven’s near-term priorities at D Zone include:

1. Completing GOH26-14 and evaluating additional drill targets within the Middle D area.
2. Completing geological logging, sampling and submission of mineralized drill core for laboratory analysis.
3. Integrating drill-hole information into updated geological plans and cross-sections to evaluate the potential continuity and orientation of mineralization.
4. Reviewing the current drill results in the context of historical drilling and 2025 surface sampling.
5. Reporting assay results as they become available and have undergone appropriate quality assurance and quality control review.

The Company will provide further updates as exploration progresses.

Qualified Person:

The technical and scientific information contained in this news release has been reviewed and approved by Raymond Wladichuk, P.Geo., who is a non-independent Qualified Person as defined under NI 43-101 and a consultant of the Company.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious and base metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws, that exploration activities at the D Zone, including the completion of drill hole GOH26-14, geological logging, sampling and the submission of drill core for laboratory analysis, will proceed as planned and without material delay, that laboratory assay results will be received in a timely manner, that the Company’s geological interpretations of visual observations and pXRF readings are reasonable, and that weather, site access and the availability of drilling equipment, contractors and personnel will not adversely affect the program.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, including the risk that laboratory assay results may not confirm visual observations or pXRF readings or may not indicate economically significant grades, the risk that historical results cannot be verified or are not representative of current drilling, changes in geological interpretation, adverse weather and seasonal access conditions in northern British Columbia, the availability of drilling equipment, contractors and personnel, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious and base metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• statements regarding the Company’s ongoing diamond drilling program at the D Zone, including the completion of drill hole GOH26-14 and the evaluation of additional drill targets within the Middle D area;
• the anticipated completion of geological logging, sampling and the submission of mineralized drill core for laboratory analysis, and the timing of receipt and reporting of assay results following appropriate quality assurance and quality control review;
• statements regarding the potential for laboratory assay results to differ from preliminary pXRF readings and visual observations;
• the interpretation that contrasting mineral assemblages may reflect different mineralization conditions within the D Zone system, and the expectation that such observations will help guide ongoing geological interpretation and exploration targeting;
• the Company’s investigation of whether the sulphide mineralization encountered in current drilling is associated with the historically documented mineralized system, and how the mineralized intervals relate to one another;
• the integration of drill-hole information into updated geological plans and cross-sections to evaluate the potential continuity and orientation of mineralization, and the review of current drill results in the context of historical drilling and 2025 surface sampling;
• statements regarding the potential of the D Zone, the polymetallic character of the target and the Company’s ongoing tungsten exploration at Kuhn; and
• the Company’s intention to provide further updates as exploration progresses.

Infographics accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/c08b8c09-ac4b-4082-a218-c2f923a3fc8c

https://www.globenewswire.com/NewsRoom/AttachmentNg/f3241633-3251-4765-abb4-3ffb3f8e2693

https://www.globenewswire.com/NewsRoom/AttachmentNg/2d71132e-f55b-425a-b4e4-acc793cdd7b6

Deep Isolation-sponsored event will bring together leaders in nuclear energy, finance and civil society to explore responsible power growth

PLANO, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that President and Chief Executive Officer Rod Baltzer will participate in The energy horizon: responsible power growth, an Economist Enterprise event scheduled for Nov. 9 at the Yale Club in New York City. The event will bring together leaders from the energy, finance and civil society sectors to explore how nuclear power can help meet rising electricity demand.

Baltzer will be joined by Shawn Reynolds, portfolio manager at VanEck, and Laura Hermann, deputy executive director of Energy Communities Alliance. The discussion will examine the opportunities and responsibilities associated with expanding nuclear energy, including the role of financing, public confidence and sustainable waste disposal solutions.

“As global energy demand accelerates, nuclear power has an increasingly important role to play in delivering reliable, low-carbon electricity,” said Baltzer. “But responsible nuclear growth requires us to think beyond electricity generation and address the entire nuclear lifecycle, including permanent waste disposal. We are excited to join Economist Enterprise and fellow industry leaders to explore how innovation, investment and community collaboration can help build a sustainable nuclear future.”

Deep Isolation is advancing deep borehole disposal technology designed to provide a safe, scalable and potentially cost-effective pathway for the permanent isolation of spent nuclear fuel and high-level radioactive waste. The Company’s participation in the Economist Enterprise event reflects its commitment to supporting responsible nuclear energy expansion through scientifically grounded waste management solutions.

To register for the free event, visit: https://events.economistenterprise.com/custom-events/the-energy-horizon/

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at InvestorRelations@deepisolation.com or CorpSec@deepisolation.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/37c5d20c-49c5-4ee4-9c45-75035810867a

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54689.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more of follow us on LinkedIn and X.

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

• Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
• One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from October 21-25, 2026, in Denver, CO.

“The data being presented at Kidney Week 2026 continue to build a more cohesive picture of how rilparencel may lead to stabilization of kidney function,” said Bruce Culleton, M.D., CEO of ProKidney. “Across multiple complementary non-clinical models, we are seeing evidence supporting an adaptive, multifactorial mechanism that involves attenuation of oxidative damage, metabolic dysregulation, and pro-inflammatory signaling, while supporting vascular and tubular repair within diseased and injured kidney cells. Importantly, these mechanistic observations coupled with the stabilization of kidney function observed across our recent Phase 2 studies in patients with advanced CKD and type 2 diabetes further strengthen our confidence in the ongoing Phase 3 PROACT 1 study.”

The titles for the accepted abstracts are provided below and are accessible online at: https://www.asn-online.org/education/kidneyweek/2026/program-search-abstract.aspx

Oral Presentation Details

Rilparencel Is Associated with a Graft-Adjacent Remodeling Response and Preserved Vascular Integrity in an Immunocompromised Rat CKD Model
Abstract Number: FR-OR044
Session Title: Exciting Developments in CKD Research: From Diagnostics to Management and More
Date, Time: October 23, 2026 from 4:30 PM to 6:00 PM MDT (ProKidney presentation starts at 5:40 PM)
Location: Mile High Ballroom 1D

Poster Presentation Details

A Human Microphysiological System Resolves Epithelial Inflammatory Injury Programs and Characterizes Autologous Cell Therapy Responses in a CKD Injury Model
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1128

Long-Duration Air-Liquid Interface Culture of Human CKD Kidney Biopsies Enables Ex Vivo Study of Disease Biology and Tissue-Context-Specific Effects of Kidney-Targeted Therapies
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1129

Metabolic Transitioning During Manufacturing of Renal Cell Therapy Candidate Rilparencel
Session Title: CKD: Mechanisms of Injury and Fibrosis – 2
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0236

Renal Autologous Cell Therapy for CKD with Diabetes: Pooled Safety and Efficacy Results from a Phase 2 Program in a Subset of Participants with Key Phase 3 Eligibility Characteristics
Session Title: CKM: Clinical – Trials, Epidemiology, and Biomarkers
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0498

GPX4-Associated Cytoprotective Activity of an Autologous Cell Therapy in Human In Vitro and Ex Vivo CKD Models
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0013

Rilparencel Manufacturing Induces Transcriptional Dedifferentiation Leading to Two Distinct Populations with Retained Tubular Lineage Memory
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0014

Longitudinal Secretome Characterization of Renal Cell Therapy Candidate Rilparencel During Manufacturing
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0015

Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead investigational product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com

– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –

– Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1’27 –

WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of Verrica’s Board of Directors. As a result of the achievement of these milestones, the full $27.5 million of non-dilutive capital under the facility is now available to Verrica, with the first $12.5 million having been funded in September.

“Verrica’s achievement of these milestones resulted directly from the momentum our team has built with YCANTH,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “We committed to clear revenue, growth and operational goals when we closed this facility in August, and we delivered on them. Importantly, the capital now available to Verrica by this facility allows us to complete our two pivotal studies in the common warts program, with readouts from the studies expected in the first quarter and in mid-2027, respectively. Under the facility, we have no obligation to make scheduled principal or interest cash payments during the term of the facility, and the favorable covenant package allows us to fully utilize our cash to support our growth. On behalf of all of us at Verrica, I would like to again thank Paul Manning for his confidence in our progress and for providing this highly flexible funding to support our programs.”

“Verrica’s execution over the past several months reinforces my confidence in the team and in YCANTH,” said Paul B. Manning, Chairman of Verrica’s Board of Directors. “I am pleased to continue supporting the Company as it builds on this progress.”

Terms of the Credit Agreement

Under the terms of credit agreement, Verrica may borrow up to $27.5 million from time to time, at its option. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The term loans will mature on December 31, 2030. The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries.

About YCANTH® (VP-102) 

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum.

Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay as little as $0 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

YCANTH is also approved for the treatment of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts.

About Verrica Pharmaceuticals Inc. 

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s ability to borrow funds under the credit facility, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — GPGI, Inc. (NYSE: GPGI), a diversified multi-industry platform for companies with great positions in good industries, today announced it will host a conference call on Thursday, November 5, 2026, at 8:00 a.m. Eastern Standard Time (EST) to discuss its financial results for the third quarter ended September 30, 2026. GPGI’s earnings results will be reported in a press release prior to the call.

GPGI’s leadership team will host the conference call, followed by a question-and-answer session.

Date: Thursday, November 5, 2026
Time: 8:00 a.m. EST
Live webcast registration link: here

We encourage all participants to register at least 15 minutes prior to the 8:00 a.m. EST start time. A live webcast and replay will be available on GPGI’s website at https://gpgi.com/events-presentations/. If you have any difficulty registering for the conference call, please contact GPGI at ir@gpgi.com.

About GPGI

GPGI, Inc. (NYSE: GPGI) is a diversified, multi-industry platform for companies with great positions in good industries. The platform is managed by Resolute Holdings Management, Inc. (NYSE: RHLD) and is purpose-built to acquire, own, and scale high-quality businesses led by great operators, benefiting from a permanent capital base and the systematic deployment of the Resolute Operating System. GPGI currently consists of CompoSecure and Husky – two market leaders with best-in-class financials and durable opportunities for growth. For more information, please visit GPGI.com.

GPGI Contact
ir@gpgi.com

Segment to air Sunday, October 25, at 5:30 p.m. ET on Fox Business Network

CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it will be featured on Health Uncensored with Dr. Drew, a national health television series hosted by Dr. Drew Pinsky, in a segment on non-invasive approaches to delivering investigational therapies to brain tumors.

Fox Business Network will carry the segment on Sunday, October 25, 2026, at 5:30 p.m. ET / 2:30 p.m. PT. Air dates and times are subject to change.

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, and Thomas Chen, MD, PhD, Founder, Chief Medical Officer and Chief Scientific Officer of NeOnc, join Dr. Drew to discuss how NeOnc’s intranasal approach is designed to reach brain tumors directly, without the limitations of surgery and systemic chemotherapy.

During the segment, Mr. Heshmatpour describes brain cancer as a growing problem and discusses the Company’s investigational intranasal NEO100 program, which is in clinical development in both adults and children. Speaking about what the program could mean for patients, he says: “We believe that we will make a significant impact in the standard of care for adults and kids suffering with brain cancer.”

Additionally, in the segment, Dr. Chen explains how the same mechanism meant to protect the brain actually makes brain tumors so difficult to treat with traditional approaches, and how NeOnc is working to overcome that challenge.

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established.

About Health Uncensored with Dr. Drew

Health Uncensored with Dr. Drew is a health and wellness program hosted by Dr. Drew Pinsky, a board-certified physician in Internal and Addiction Medicine, as well as a television host, author and public speaker. Dr. Drew engages with a range of experts, thought leaders, celebrities and everyday people to provide viewers with practical advice, evidence-based information and discussions about wellness, mental health and the importance of proactive health management.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches.

For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s clinical development programs and the clinical potential of NEO100. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.

The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ^® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ^® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-Q

FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.

Nasdaq’s determination follows Celularity’s October 20, 2026 filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026. Nasdaq confirmed that the reporting deficiency matter is now closed.

As previously disclosed, on September 11, 2026, Nasdaq confirmed that Celularity had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2), closing both matters. With today’s notification, each of these three previously disclosed deficiency matters has been closed.

“We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “Our shareholders deserve better. With our filings now current, we must address the recurring delays. We have begun a process to overhaul our finance organization and establish the reporting discipline expected of a public company.”

“The need to strengthen the finance organization was clear when I invested in Celularity, and the late filings did not change my conviction in Celularity’s science and commercial potential,” said Philip A. Barach, a recently appointed director and investor in Celularity. “The Board is working with Dr. Hariri to identify experienced finance professionals who can carry that work forward. Our focus is on building a team that can consistently meet ongoing financial reporting obligations as we aggressively pursue the opportunities ahead.”

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused products.

For more information, visit www.celularity.com.

Forward-Looking Statements

This release contains forward-looking statements under applicable federal securities laws, including statements concerning Celularity’s finance organization overhaul, expected improvements in financial reporting, ability to maintain compliance with Nasdaq listing requirements, and execution of its regenerative longevity strategy. These statements reflect management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. Such risks include Celularity’s ability to implement organizational and reporting improvements, maintain sufficient resources to meet its reporting obligations, and satisfy continued listing requirements, together with other risks described in Celularity’s SEC filings. Celularity undertakes no obligation to update these statements except as required by law.

Contact

info@celularity.com